RxDoctor Payments Data

Lydia Battle-Williams, PA

Physician Assistant · Charlotte, NCNPI 1346343159

Payments from drug & device makers

$4,271in general payments, 2019–2025

Across 62 payments — averaging $68.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$387
  • GSK$365
  • Paratek Pharmaceuticals, Inc.$250
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$196
  • Biohaven Pharmaceuticals, Inc.$191
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$4,271100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,271 in reported general payments places this provider in the 90th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$4,616
Medicare patients
21
Services billed
46

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide14$21,523
FarxigaDapagliflozin Propanediol18$19,715
TradjentaLinagliptin21$19,640
LinzessLinaclotide23$12,876
XareltoRivaroxaban17$9,843
Mesalamine DrMesalamine12$8,125
Xigduo XrDapaglifloz Propaned/Metformin18$6,164
Humalog Kwikpen U-100Insulin Lispro13$5,475
SymbicortBudesonide/Formoterol Fumarate26$2,475
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$2,259
Levemir FlexpenInsulin Detemir11$2,091
Lidocaine15$2,071
Gabapentin59$1,650
Albuterol Sulfate HfaAlbuterol Sulfate47$1,189
Omeprazole91$858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,380$21,52314 claims
AbbVieLinzess$387$12,87623 claims
Johnson & JohnsonXarelto$99$9,84317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →